Roberto Pili Selected Research

tasquinimod

1/2016	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
2/2015	Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
11/2014	Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
1/2014	Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer.
4/2013	Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
10/2011	Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
12/2006	Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberto Pili Research Topics

Disease

91	Neoplasms (Cancer) 12/2021 - 05/2002
50	Prostatic Neoplasms (Prostate Cancer) 11/2020 - 11/2004
48	Renal Cell Carcinoma (Grawitz Tumor) 12/2021 - 01/2004
13	Neoplasm Metastasis (Metastasis) 12/2021 - 07/2007
13	Carcinoma (Carcinomatosis) 12/2018 - 06/2005
11	Disease Progression 11/2020 - 09/2009
10	Fatigue 01/2019 - 08/2006
9	Hypoxia (Hypoxemia) 09/2020 - 09/2004
8	Urinary Bladder Neoplasms (Bladder Cancer) 11/2020 - 12/2013
6	Kidney Neoplasms (Kidney Cancer) 05/2020 - 07/2007
5	Hypertension (High Blood Pressure) 01/2019 - 08/2009
4	Melanoma (Melanoma, Malignant) 02/2015 - 01/2004
4	Colonic Neoplasms (Colon Cancer) 01/2014 - 07/2009
3	Diarrhea 07/2017 - 08/2006
3	Exanthema (Rash) 05/2016 - 08/2006
2	Febrile Neutropenia 10/2018 - 06/2008
2	Cancer Pain 01/2018 - 01/2016
2	Anemia 07/2017 - 01/2016
2	Hand-Foot Syndrome 05/2016 - 08/2009
2	Breast Neoplasms (Breast Cancer) 12/2013 - 05/2002
2	Carcinogenesis 07/2013 - 05/2002
2	Heart Failure 09/2011 - 08/2006
2	Adenocarcinoma 01/2011 - 08/2007

Drug/Important Bio-Agent (IBA)

23	Histone Deacetylase InhibitorsIBA 01/2020 - 09/2004
21	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 09/2003
18	Sunitinib (Sutent)FDA Link 01/2018 - 08/2009
14	Proteins (Proteins, Gene)FDA Link 12/2018 - 12/2002
13	Pharmaceutical PreparationsIBA 09/2020 - 05/2006
13	Histone Deacetylases (Histone Deacetylase)IBA 01/2020 - 01/2006
12	AndrogensIBA 01/2020 - 08/2006
9	entinostat (MS 275)IBA 12/2017 - 05/2005
9	Tyrosine Kinase InhibitorsIBA 02/2015 - 09/2004
7	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2017
7	Androgen Receptors (Androgen Receptor)IBA 11/2020 - 01/2008
7	Histones (Histone)IBA 09/2020 - 05/2002
7	Interleukin-2 (IL2)IBA 12/2017 - 08/2007
7	tasquinimodIBA 01/2016 - 12/2006
6	Biomarkers (Surrogate Marker)IBA 09/2020 - 10/2011
5	Hormones (Hormone)IBA 11/2020 - 09/2005
5	PanobinostatIBA 01/2020 - 01/2006
5	Cisplatin (Platino)FDA LinkGeneric 11/2019 - 02/2016
5	Biological ProductsIBA 01/2018 - 09/2004
5	Bevacizumab (Avastin)FDA Link 03/2017 - 06/2004
5	Prostate-Specific Antigen (Semenogelase)IBA 01/2017 - 12/2009
5	Docetaxel (Taxotere)FDA Link 01/2014 - 08/2006
4	Peptides (Polypeptides)IBA 12/2021 - 01/2005
4	Mechanistic Target of Rapamycin Complex 1IBA 11/2020 - 01/2011
4	EnzymesIBA 01/2020 - 07/2009
4	Axitinib (AG 013736)IBA 01/2019 - 01/2015
4	LuciferasesIBA 09/2015 - 06/2005
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2015 - 09/2003
4	Angiogenesis InhibitorsIBA 04/2013 - 01/2006
3	VaccinesIBA 12/2021 - 01/2012
3	Phosphotransferases (Kinase)IBA 01/2020 - 09/2003
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 12/2013
3	Everolimus FDA Link 01/2020 - 01/2011
3	enzalutamideIBA 01/2020 - 04/2013
3	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 08/2016
3	Dietary ProteinsIBA 12/2018 - 12/2013
3	SurvivinIBA 12/2018 - 09/2004
3	RNA (Ribonucleic Acid)IBA 12/2018 - 02/2015
3	afliberceptIBA 12/2017 - 07/2007
3	Antineoplastic Agents (Antineoplastics)IBA 02/2015 - 01/2011
3	vadimezanIBA 02/2012 - 04/2008
3	LAQ824IBA 01/2007 - 09/2004
3	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 06/2005 - 05/2002
2	CytokinesIBA 06/2020 - 01/2017
2	Interleukin-6 (Interleukin 6)IBA 06/2020 - 12/2009
2	abirateroneIBA 01/2020 - 04/2013
2	PolyaminesIBA 01/2020 - 11/2017
2	taxaneIBA 01/2020 - 12/2011
2	MTOR InhibitorsIBA 01/2020 - 02/2012
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 03/2007
2	CrizotinibIBA 01/2019 - 01/2015
2	Messenger RNA (mRNA)IBA 01/2018 - 12/2017
2	SeleniumIBA 04/2017 - 07/2012
2	Vorinostat FDA Link 03/2017 - 12/2009
2	Sorafenib (BAY 43-9006)FDA Link 03/2017 - 05/2016
2	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 03/2016 - 01/2012
2	ChromatinIBA 01/2016 - 01/2008
2	Drug CombinationsIBA 07/2015 - 06/2005
2	pazopanib FDA Link 02/2015 - 12/2013
2	cabazitaxel FDA Link 08/2013 - 04/2013
2	Prednisone (Sone)FDA LinkGeneric 08/2013 - 02/2011
2	sipuleucel-T (APC8015)FDA Link 04/2013 - 08/2011
2	Capsules (Microcapsules)IBA 01/2013 - 07/2007
2	Hypoxia-Inducible Factor 1IBA 07/2012 - 09/2006
2	2-MethoxyestradiolIBA 04/2012 - 12/2011
2	Acetic Acid (Vinegar)FDA LinkGeneric 02/2012 - 05/2010
2	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 10/2011 - 01/2011
2	Mitoxantrone (Novantrone)FDA LinkGeneric 02/2011 - 06/2004
2	TOR Serine-Threonine KinasesIBA 01/2011 - 06/2008
2	Interferon-alpha (Interferon Alfa)IBA 08/2009 - 01/2004

Therapy/Procedure

48	Therapeutics 01/2021 - 05/2002
18	Castration 11/2020 - 06/2008
11	Drug Therapy (Chemotherapy) 11/2019 - 06/2004
10	Immunotherapy 12/2021 - 09/2011
4	Nephrectomy 01/2016 - 09/2011
2	Neoadjuvant Therapy 02/2016 - 12/2013
2	Radiotherapy 11/2010 - 03/2007